Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes (REALISED)

Novo Nordisk

Status: Not yet enrolling

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Semaglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT06507475

NN9924-7830

U1111-1294-2999 (Other Identifier)

Details and patient eligibility

About

This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.

Enrollment: 209 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult Thai male or female patients aged greater than or equal to (≥) 18 years.
• Diagnosed with T2D either through International Classification of Diseases (ICD) code or by physician's description such as documentation in the medical record, and who have not previously been treated with injectable glucose-lowering medication.
• At least one recent or closest Glycated Haemoglobin (HbA1c) test value available and documented less than or equal to 12 weeks prior to the initiation of oral semaglutide.
• Had initiated oral semaglutide for diabetes during the target selection period of April 2022 to December 2023. All required data for collection should already be accessible prior to the initiation of data collection.
• Treated with oral semaglutide for at least 6 months without interruption or discontinuation.

Exclusion criteria

• Previous participation in this study. Participation is defined as having given informed consent in this study (if applicable).
• Participants with any diagnosis of type 1 diabetes (T1D).
• Medical records documenting prior or ongoing treatment with injectable glucose-lowering treatment.

Trial design

209 participants in 1 patient group

Semaglutide

Description:

Participants diagnosed with type 2 diabetes (T2D) who had initiated once-daily oral semaglutide during the target selection period of April 2022 to December 2023 and have not previously been treated with injectable glucose-lowering medication in routine clinical practice.

Treatment:

Drug: Semaglutide